Recent Finacing
Recent Raise
Seaside Therapeutics is a clinical-stage Cambridge, MA biopharmaceutical developing STX209 (Phase 2) for Fragile X and autism and STX107 (Phase 1) for Fragile X.
Focus Areas
Total Raised
Funding round
